GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced that the Arexvy vaccine (MAL24086007ARZ) has been approved in Malaysia for respiratory syncytial virus (RSV). RSV is a common respiratory ...

The GSK share price has had a rotten few years and now it's heading south yet again. Investor Harvey Jones continues to hang ...

Arexvy has been approved in Malaysia for RSV (respiratory syncytial virus), for older adults aged 60 and above. The vaccine ...

GSK PLC GSK shares inched up 0.20% to £15.31 Tuesday, on what proved to be an all-around favorable trading session for the ...

GSK plc (GSK, GSK.L) announced the European Medicine Agency's Committee for Medicinal Products for Human Use or CHMP has recommended ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on GlaxoSmithKline (GB:GSK – Research Report), Sonova Holding AG (CH:SOON – Research Report) and Corbus Pharmaceuticals ...

智通财经APP获悉，葛兰素史克 (GSK.US)宣布，其“first-in-class”抗体疗法Nucala（mepolizumab），在治疗成人慢性阻塞性肺病（COPD）患者的3期临床试验MATINEE中获得积极结果。这一试验结果将支持GSK与监管机构讨论，以提交申请扩展Nucala的适应症。

The trial testing the immune response of co-administration of GSK's blockbuster vaccines, Shingrix and Arexvy, in adults over ...

Shares of GSK PLC GSK inched down 0.55% to £15.28 Monday, on what proved to be an all-around favorable trading session for ...

British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...

智通财经APP获悉，葛兰素史克 (GSK.US)治疗哮喘的畅销药物Nucala在用于治疗另一种慢性肺部疾病时呈现出积极效果，或为该产品开辟了一条新的增长途径。 Nucala于2015年首次在美国被批准用于治疗严重哮喘，目前是该公司表现最好的药物，去年的销售额为17亿英镑 (22.4亿美元)。

TD Cowen维持对GlaxoSmithKline (GSK:LN) (NYSE: GSK)的"持有"评级，目标价保持在1,790.00英镑不变。该公司的立场是在GlaxoSmithKline报告其哮喘药物depemokimab的III期试验结果积极之后做出的，这与关键意见领袖（KOL）预期的约50%哮喘发作减少率一致。这一表现与已获批准的IL-5抑制剂相似。